# A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

> **NCT06398444** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sinotau Pharmaceutical Group** · enrollment: 74 (estimated)

## Conditions studied

- Advanced Neuroendocrine Neoplasm

## Interventions

- **DRUG:** Lutetium[177Lu] Oxodotreotide Injection

## Key facts

- **NCT ID:** NCT06398444
- **Lead sponsor:** Sinotau Pharmaceutical Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2027-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06398444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06398444, "A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06398444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*